Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer

Xu Steven Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, Peter De Porre, An Vermeulen, Italo Poggesi, Partha Nandy

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background and Objectives: Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone acetate plus prednisone. This analysis aimed to investigate the abiraterone exposure–PSA dynamics relationship in mCRPC. Methods: Abiraterone pharmacokinetics–PSA models were constructed using data from the COU-AA-301 (chemotherapy-pretreated) and COU-AA-302 (chemotherapy-naïve) trials comparing abiraterone acetate 1000 mg/day plus prednisone 5 mg twice daily with prednisone alone in mCRPC. The drug effect–PSA dynamics relationship was modeled as a function of selected pharmacokinetic measures. The influences of baseline demographic variables, laboratory values, and disease status on PSA dynamics were assessed. Results: A tumor growth inhibition model best described PSA dynamics post-treatment with abiraterone acetate. Abiraterone acetate treatment in chemotherapy-pretreated and chemotherapy-naïve patients increased the PSA decay rate (kdec) to the same extent (1.28-fold, 95 % confidence interval [CI] 0.58–1.98; and 0.93-fold, 95 % CI 0.6–1.27, respectively). Lower baseline lactate dehydrogenase and higher baseline testosterone significantly increased kdec. Findings from our analysis suggest a maximum-effect relationship between abiraterone trough concentration and PSA dynamics in both patient populations. The majority of patients had a steady-state trough concentration greater than the estimated half maximal effective concentration. Conclusion: The model appropriately described the exposure–response relationship between abiraterone and PSA dynamics in chemotherapy-pretreated and chemotherapy-naïve patients following oral administration of abiraterone acetate.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalClinical Pharmacokinetics
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint Dive into the research topics of 'Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Xu, X. S., Ryan, C. J., Stuyckens, K., Smith, M. R., Saad, F., Griffin, T. W., Park, Y. C., Yu, M. K., De Porre, P., Vermeulen, A., Poggesi, I., & Nandy, P. (2017). Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics, 56(1), 55-63. https://doi.org/10.1007/s40262-016-0425-0